nasdaqA Drug for an Untreatable Skin Disease Just Cleared Its First Clinical Hurdle

Netherton Syndrome is a rare genetic skin disease with no approved treatment available in the United States. On August 28, Quoin Pharmaceuticals said the first six patients to complete twelve weeks on its experimental lotion had cleared the statistical bar the company had set in advance for the interim review.

Four of those six patients improved by at least one grade on the primary physician skin assessment, achieving statistical significance with a p-value of 0.0087 against a pre-set threshold of 0.0215. A secondary measure of overall patient-rated change cleared the same bar. No treatment-related serious adverse events were reported.

Two questions matter most to anyone holding the stock: does the drug work, and can the company afford to find out? The interim data offered a provisional answer to the first. On the same day, a separate announcement addressed the second.

Quoin said it had agreed to raise up to $50 million from a group of healthcare-focused institutional investors, including Sirenia Capital Management, Sphera Healthcare, AIGH Capital Management, Nantahala Capital, StemPoint Capital, and Stonepine Capital Management, along with members of management and the board. About $30.8 million arrives upfront. The remaining roughly $19.2 million depends on whether investors choose to exercise the warrants included in the deal. The company says the combined net proceeds, assuming full exercise, are expected to fund operations into the second half of 2029.

Shares closed 18.72% higher at $6.1200 after both announcements, on dollar volume of about $228.5 million.

Those warrants carry a deadline tied directly to the trial's outcome. They expire on the earlier of five years from closing or 30 days after Quoin publicly announces that the full trial has met its primary endpoint — which the company says it expects to report in the second quarter of 2027. A positive readout starts a 30-day clock for investors to decide whether to exercise and deliver the remaining $19.2 million. The company says it expects to complete enrollment of all 20 participants by the end of 2026.